Dr Alan Robertson
Dr Alan Robertson has an extensive international career in new drug design and development and commercialisation of research. While working for Wellcome (now GSK) in the UK, Dr Robertson invented the antimigraine drug, Zomig, and spearheaded its development into clinical trials.
Previously, Dr Robertson was the inaugural CEO and Managing Director of Pharmaxis Ltd, responsible for the development to international approval of a new treatment for cystic fibrosis. In that role, he established a drug discovery capability within Pharmaxis that led to a number of important discoveries including a new drug for liver inflammation, that has been licensed to Boehringer Ingelheim
Currently, Dr Robertson, is the CEO and Managing Director of Alsonex, a clinical stage company developing a new treatment for neurodegenerative diseases including Motor Neuron Disease and Parkinson’s Disease. He is also Chairman of GenieUs, a genomics based company exploring new treatment options for motor neuron disease, and Chairman of AllVascular, a company developing a vascular access device for treating cancer.
Dr Robertson serves on the Scientific Advisory Boards of Pharmaxis Limited, The Cure Brain Cancer Foundation, and the Australian Cancer Research Foundation (ACRF) Drug Discovery Centre.